Which has higher earnings & valuation, GDR or GENI?

GENinCode has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio genedrive £929K 20.34 -£21.22M -£0.79 N/A GENinCode £3.08M 2.20 -£6.10M -£2.08 N/A

Is GDR or GENI more profitable?

GENinCode has a net margin of -185.47% compared to genedrive's net margin of -500.75%. GENinCode's return on equity of -409.40% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets genedrive -500.75% -1,044.57% -74.09% GENinCode -185.47% -409.40% -63.99%

Which has higher earnings and valuation, AGL or GENI?

GENinCode has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A GENinCode £3.08M 2.20 -£6.10M -£2.08 N/A

Is AGL or GENI more profitable?

GENinCode has a net margin of -185.47% compared to ANGLE's net margin of -1,444.04%. ANGLE's return on equity of -191.36% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets ANGLE -1,444.04% -191.36% -29.89% GENinCode -185.47% -409.40% -63.99%

Does the media favor AGL or GENI?

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.75 beat GENinCode's score of 0.25 indicating that ANGLE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANGLE 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GENinCode 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GENI or VRCI more profitable?

GENinCode has a net margin of -185.47% compared to Verici Dx's net margin of -193.05%. Verici Dx's return on equity of -138.93% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets GENinCode -185.47% -409.40% -63.99% Verici Dx -193.05% -138.93% -26.14%

Does the media favor GENI or VRCI?

In the previous week, GENinCode and GENinCode both had 1 articles in the media. GENinCode's average media sentiment score of 0.25 beat Verici Dx's score of -1.84 indicating that GENinCode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GENinCode 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Does the media refer more to PRM or GENI?

In the previous week, Proteome Sciences and Proteome Sciences both had 1 articles in the media. Proteome Sciences' average media sentiment score of 0.75 beat GENinCode's score of 0.25 indicating that Proteome Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Proteome Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GENinCode 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GENinCode (GENI) Competitors

GBX 0.90 +0.03 (+2.86%)

As of 06:15 AM Eastern

Compare

GENI vs. GDR, YGEN, AGL, VRCI, and PRM

Should you buy GENinCode stock or one of its competitors? GENinCode's main competitors and comparable companies include genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), Verici Dx (VRCI), and Proteome Sciences (PRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does GENinCode compare to genedrive?

genedrive (LON:GDR) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

GENinCode has a net margin of -185.47% compared to genedrive's net margin of -500.75%. GENinCode's return on equity of -409.40% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
genedrive	-500.75%	-1,044.57%	-74.09%
GENinCode	-185.47%	-409.40%	-63.99%

genedrive has a beta of 0.968, meaning that its stock price is 3% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

GENinCode has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
genedrive	£929K	20.34	-£21.22M	-£0.79	N/A
GENinCode	£3.08M	2.20	-£6.10M	-£2.08	N/A

0.1% of genedrive shares are owned by institutional investors. Comparatively, 11.4% of GENinCode shares are owned by institutional investors. 28.1% of genedrive shares are owned by company insiders. Comparatively, 8.4% of GENinCode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GENinCode had 1 more articles in the media than genedrive. MarketBeat recorded 1 mentions for GENinCode and 0 mentions for genedrive. GENinCode's average media sentiment score of 0.25 beat genedrive's score of 0.00 indicating that GENinCode is being referred to more favorably in the news media.

Company	Overall Sentiment
genedrive	Neutral
GENinCode	Neutral

Summary

GENinCode beats genedrive on 9 of the 13 factors compared between the two stocks.

How does GENinCode compare to Yourgene Health?

GENinCode (LON:GENI) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, GENinCode had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for GENinCode and 0 mentions for Yourgene Health. GENinCode's average media sentiment score of 0.25 beat Yourgene Health's score of 0.00 indicating that GENinCode is being referred to more favorably in the media.

Company	Overall Sentiment
GENinCode	Neutral
Yourgene Health	Neutral

11.4% of GENinCode shares are held by institutional investors. Comparatively, 23.3% of Yourgene Health shares are held by institutional investors. 8.4% of GENinCode shares are held by company insiders. Comparatively, 64.4% of Yourgene Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Yourgene Health has a net margin of -27.55% compared to GENinCode's net margin of -185.47%. Yourgene Health's return on equity of -27.06% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-185.47%	-409.40%	-63.99%
Yourgene Health	-27.55%	-27.06%	-6.71%

GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

GENinCode has higher earnings, but lower revenue than Yourgene Health. GENinCode is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£3.08M	2.20	-£6.10M	-£2.08	N/A
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A

Summary

Yourgene Health beats GENinCode on 8 of the 12 factors compared between the two stocks.

How does GENinCode compare to ANGLE?

ANGLE (LON:AGL) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

GENinCode has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
GENinCode	£3.08M	2.20	-£6.10M	-£2.08	N/A

17.5% of ANGLE shares are held by institutional investors. Comparatively, 11.4% of GENinCode shares are held by institutional investors. 2.7% of ANGLE shares are held by insiders. Comparatively, 8.4% of GENinCode shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.75 beat GENinCode's score of 0.25 indicating that ANGLE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANGLE	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GENinCode	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GENinCode has a net margin of -185.47% compared to ANGLE's net margin of -1,444.04%. ANGLE's return on equity of -191.36% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-1,444.04%	-191.36%	-29.89%
GENinCode	-185.47%	-409.40%	-63.99%

ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Summary

GENinCode beats ANGLE on 7 of the 12 factors compared between the two stocks.

How does GENinCode compare to Verici Dx?

GENinCode (LON:GENI) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

GENinCode has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, suggesting that its share price is 22% more volatile than the broader market.

In the previous week, GENinCode and GENinCode both had 1 articles in the media. GENinCode's average media sentiment score of 0.25 beat Verici Dx's score of -1.84 indicating that GENinCode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GENinCode	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

GENinCode has higher earnings, but lower revenue than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£3.08M	2.20	-£6.10M	-£2.08	N/A
Verici Dx	£3.66M	1.25	-£6.56M	-£0.90	N/A

GENinCode has a net margin of -185.47% compared to Verici Dx's net margin of -193.05%. Verici Dx's return on equity of -138.93% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-185.47%	-409.40%	-63.99%
Verici Dx	-193.05%	-138.93%	-26.14%

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 15.9% of Verici Dx shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Verici Dx beats GENinCode on 7 of the 12 factors compared between the two stocks.

How does GENinCode compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Proteome Sciences has higher revenue and earnings than GENinCode. Proteome Sciences is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteome Sciences	£3.77M	1.35	-£4.08M	-£1.04	N/A
GENinCode	£3.08M	2.20	-£6.10M	-£2.08	N/A

In the previous week, Proteome Sciences and Proteome Sciences both had 1 articles in the media. Proteome Sciences' average media sentiment score of 0.75 beat GENinCode's score of 0.25 indicating that Proteome Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Proteome Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GENinCode	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Proteome Sciences has a net margin of -61.46% compared to GENinCode's net margin of -185.47%. Proteome Sciences' return on equity of 23.85% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Proteome Sciences	-61.46%	23.85%	-19.25%
GENinCode	-185.47%	-409.40%	-63.99%

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 11.4% of GENinCode shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by insiders. Comparatively, 8.4% of GENinCode shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Proteome Sciences beats GENinCode on 8 of the 12 factors compared between the two stocks.

Get GENinCode News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENI vs. The Competition

Export

Metric	GENinCode	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£6.78M	£10.51B	£7.31B	£2.90B
Dividend Yield	N/A	1.45%	2.52%	6.21%
P/E Ratio	-0.43	75.12	274.39	366.50
Price / Sales	2.20	108.29	685.29	90,010.18
Price / Cash	0.83	27.90	77.80	27.89
Price / Book	0.55	6.07	10.44	6.33
Net Income	-£6.10M	£56.67B	£3.49B	£5.89B
7 Day Performance	N/A	2.75%	-0.92%	0.44%
1 Month Performance	N/A	2.83%	-4.22%	6.02%
1 Year Performance	-78.85%	40.29%	16.40%	19.54%

GENinCode Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENI GENinCode	N/A	GBX 0.90 +2.9%	N/A	-79.0%	£6.78M	£3.08M	N/A	2,300
GDR genedrive	N/A	GBX 1.23 -1.5%	N/A	+370.6%	£19.77M	£929K	N/A	43	Gap Up
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-22.3%	£7.58M	£2.62M	N/A	650	News Coverage Gap Up
VRCI Verici Dx	N/A	GBX 0.24 +5.8%	N/A	-59.0%	£5.44M	£3.66M	N/A	19	Negative News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GENI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GENinCode (GENI) Competitors